Pay in 4 interest-free payments of $7.00 Learn more
Ships within 48 hours · Estimated delivery Nov 11 - Nov 16
TB-500 and Thymosin Beta-4 are also prohibited by WADA/USADA under S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), applicable at all times both in-competition and out-of-competition TB-500 / Thymosin Beta-4 Clinical Trials: The RGN-352 and RGN-259 Programs RegeneRx Biopharmaceuticals has pursued two clinical development programs for Thymosin Beta-4, providing the most substantial human clinical data available for any TB-500-related compound: RGN-352 (Injectable Thymosin Beta-4 for Cardiac Repair): Phase 1 trial (completed): A double-blind, placebo-controlled study enrolled 40 healthy volunteers across four cohorts of 10 subjects each, testing escalating dose levels of intravenous Thymosin Beta-4 administered daily over 14 days
Neuropathy/Nerve Support: Prevents and treats nerve pain, numbness, and neurological complications
:max_bytes(150000):strip_icc()/GettyImages-1299286851-18ab6e02931940ad963dda93851b6dc7.jpg)
Lets craft a resume that gets you noticed.
Uses: Offers a quicker and more efficient absorption than traditional oral forms, providing general antioxidant support and mild detoxification without the invasiveness of IV administration
Injury Healing In animal models, BPC-157 has been shown to improve healing and tissue regeneration in GI tissues, as well as muscles, ligaments, skin, bone, and tendons
US$ 21.34
US$ 26.83
US$ 20.74
